Cargando…
Fluconazole resistance in Candida species: a current perspective
Candida albicans and the emerging non-albicans Candida spp. have significant clinical relevance among many patient populations. Current treatment guidelines include fluconazole as a primary therapeutic option for the treatment of these infections, but it is only fungistatic against Candida spp. and...
Autores principales: | Berkow, Elizabeth L, Lockhart, Shawn R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546770/ https://www.ncbi.nlm.nih.gov/pubmed/28814889 http://dx.doi.org/10.2147/IDR.S118892 |
Ejemplares similares
-
Fluconazole resistance in non-albicans Candida species in the United States, 2012-2021
por: Jenkins, Emily, et al.
Publicado: (2023) -
Mutations in TAC1B: a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris
por: Rybak, Jeffrey M., et al.
Publicado: (2020) -
The relationship between the use of fluconazole & the incidence of fluconazole-resistant Candida species
por: Kuo, Chia-Chang, et al.
Publicado: (2014) -
2885. Increased incidence of fluconazole-resistant Candida parapsilosis bloodstream infections in Atlanta, Georgia 2021
por: Witt, Lucy S, et al.
Publicado: (2023) -
Pharmacodynamic Optimization for the Treatment of Invasive Candida auris Infection
por: Lepak, Alexander J, et al.
Publicado: (2017)